Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Stargazer Pharmaceuticals

Request full access

An ophthalmic biotech company focused on the development of a novel treatment option for a genetic orphan retinal disease with significant unmet medical needs

Boston, United StatesFounded 2018Biotech & Life Sciences

About Stargazer Pharmaceuticals

Stargazer Pharmaceuticals Inc is a biotech company specializing in ophthalmic treatments, particularly for Stargardt Disease, a rare genetic retinal disorder with significant unmet medical needs. The company operates in the biotechnology and pharmaceutical market, focusing on developing novel therapeutic solutions for eye diseases. Stargazer's core product, STG-001, is an indirect visual cycle modulator that reduces plasma concentrations of Retinol Binding Protein 4 (RBP4), thereby slowing down the visual cycle and accumulation of toxic retinoids in the eye. This innovative approach aims to provide a much-needed treatment option for patients suffering from Stargardt Disease.

Stargazer Pharmaceuticals primarily serves patients with rare ophthalmic conditions, working closely with healthcare providers and medical institutions. The company's business model revolves around research and development, clinical trials, and eventual commercialization of their proprietary treatments. Revenue is generated through the sale of their therapeutic products, partnerships, and potential licensing agreements.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
23.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Disease, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Nov 2020 $57M $228M Canaan · Novo Holdings · Pontifax Funds · Retinal Degeneration Fund —
EARLY VCOther financing Apr 2018 $28M $114M Undisclosed —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Stargazer Pharmaceuticals website traffic

Latest recorded traffic for Stargazer Pharmaceuticals is 140 monthly website visits, down 44% over the last three months.

Latest monthly visits140 3-month web change-44%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Stargazer Pharmaceuticals in the Boston ecosystem

Live from Dealroom

The Stargazer Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Canaan
  • Novo Holdings
  • Pontifax Funds
  • Retinal Degeneration Fund
  • venBio Partners
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Boston HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Stargazer Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Stargazer Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.